Conference DM in HF 2019
Choice of Glucose-Lowering
Pharmacotherapy in Patients With DM at High Risk for HF or With Established HF
SHAHIN NOSRATZEHI
Agenda
- Metformin
- Insulin secretoguges
- TZDs
- DPP4 inhibitors
- GLP1 analouges
- SGLT2 inhibitors
Metformin
- Among the 9 studies, 34504 patients with diabetes mellitus and HF were included, with 6624 patients (19%) using metformin
- The majority of studies evaluated the use of metformin in combination with other oral agents or insulin
- Two studies specifically evaluated the use of metformin as monotherapy
- we examined 2 important subpopulations: those with reduced left ventricular ejection fraction (LVEF) and those with concomitant chronic kidney disease.
- we further explored the potential role of metformin in patients with diabetes mellitus and HF with compromised kidney function.
